

# Phathom<sup>®</sup>

## PHARMACEUTICALS

### **Phathom Pharmaceuticals to Present at Morgan Stanley 18th Annual Global Healthcare Conference**

September 9, 2020

FLORHAM PARK, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference at 3:30 p.m. ET on Tuesday, September 15, 2020.

Company management will also participate in one-on-one meetings during the virtual conference which runs from September 14-18, 2020.

To access the live webcast and archived recordings for each presentation, visit the News & Events section of the Phathom website at <https://investors.phathompharma.com/news-events/events-and-presentations>. Recordings will be available for 60 days following the event.

#### **About Phathom**

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Company's website at [www.phathompharma.com](http://www.phathompharma.com) or follow the Company on LinkedIn at [www.linkedin.com/company/phathompharma](http://www.linkedin.com/company/phathompharma).

#### **CONTACTS**

##### **Media Contact:**

Nick Benedetto  
1-877-742-8466  
[media@phathompharma.com](mailto:media@phathompharma.com)

##### **Investor Contact:**

Todd Branning  
1-877-742-8466  
[ir@phathompharma.com](mailto:ir@phathompharma.com)